T1	DISO 116 127	metastásico
#1	AnnotatorNotes T1	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T2	CHEM 77 88	dacarbacina
#2	AnnotatorNotes T2	C0010927; dacarbazine; Organic Chemical · Pharmacologic Substance
T3	DISO 267 278	metastásico
#3	AnnotatorNotes T3	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T4	PROC 151 192	Estudio fase 3, aleatorizado, doble ciego
T5	CHEM 217 228	dacarbacina
#4	AnnotatorNotes T5	C0010927; dacarbazine; Organic Chemical · Pharmacologic Substance
T6	DISO 244 252	melanoma
#5	AnnotatorNotes T6	C0025202; melanoma; Neoplastic Process
T7	PROC 317 326	protocolo
#6	AnnotatorNotes T7	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T8	DISO 401 409	melanoma
#7	AnnotatorNotes T8	C0025202; melanoma; Neoplastic Process
T9	DISO 544 552	Melanoma
#8	AnnotatorNotes T9	C0025202; melanoma; Neoplastic Process
T10	DISO 901 909	mutación
T11	DISO 675 693	Enfermedad medible
#9	AnnotatorNotes T11	C1513041; Measurable Disease; Disease or Syndrome
T12	DISO 745 752	tumoral
#10	AnnotatorNotes T12	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C0577559; Mass of body structure; Finding
T13	DISO 776 786	enfermedad
#11	AnnotatorNotes T13	C0012634; Disease; Disease or Syndrome
T14	PROC 822 847	análisis de biomarcadores
T15	DISO 1095 1116	Metástasis cerebrales
#12	AnnotatorNotes T15	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T16	DISO 1127 1152	metástasis leptomeníngeas
#13	AnnotatorNotes T16	C1704231; Metastatic Malignant Neoplasm to the Leptomeninges; Neoplastic Process
T17	DISO 1156 1171	Melanoma ocular
#14	AnnotatorNotes T17	C0558356; Malignant melanoma of eye; Neoplastic Process
T18	DISO 1187 1213	enfermedad autoinmunitaria
#15	AnnotatorNotes T18	C0004364; Autoimmune Diseases; Disease or Syndrome
T19	PROC 1300 1312	randomizados
#16	AnnotatorNotes T19	C0034656; Randomization; Research Activity
T20	CHEM 1325 1336	Dacarbazina
#17	AnnotatorNotes T20	C0010927; dacarbazine; Organic Chemical · Pharmacologic Substance
T21	CHEM 1391 1400	nivolumab
#18	AnnotatorNotes T21	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T22	DISO 801 812	metastásica
#19	AnnotatorNotes T22	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T23	PROC 1427 1436	protocolo
#20	AnnotatorNotes T23	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T24	DISO 93 101	melanoma
#21	AnnotatorNotes T24	C0025202; melanoma; Neoplastic Process
T25	PROC 663 670	tratado
#22	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T26	DISO 986 994	mutación
T27	PROC 282 289	tratado
#23	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	ANAT 738 752	tejido tumoral
T29	PROC 880 917	pruebas de estado de mutación de V600
#24	AnnotatorNotes T29	C3248133; BRAF GENE ANALYSIS V600E VARIANT; Laboratory Procedure
T30	ANAT 1106 1116	cerebrales
#25	AnnotatorNotes T30	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T31	ANAT 1138 1152	leptomeníngeas
#26	AnnotatorNotes T31	C0228126; Leptomeninges; Body Part, Organ, or Organ Component | C1284563; Entire leptomeninges; Body Part, Organ, or Organ Component
T32	ANAT 1165 1171	ocular
#27	AnnotatorNotes T32	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T33	CHEM 57 67	BMS-936558
#28	AnnotatorNotes T33	C4552119; BMS-936558; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T34	CHEM 197 207	BMS-936558
#29	AnnotatorNotes T34	C4552119; BMS-936558; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T35	Date 13 17	2012
T36	LIVB 232 239	sujetos
#30	AnnotatorNotes T36	C0681850; Study Subject; Group
T37	Neg_cue 279 281	no
T38	Date 357 376	20 de marzo de 2013
T39	LIVB 448 455	mujeres
#31	AnnotatorNotes T39	C0043210; Woman; Population Group
T40	Age 456 465	>=18 años
T44	Neg_cue 660 662	no
T45	Neg_cue 944 946	No
T46	LIVB 974 981	sujetos
#32	AnnotatorNotes T46	C0681850; Study Subject; Group
T48	LIVB 1175 1182	Sujetos
#33	AnnotatorNotes T48	C0681850; Study Subject; Group
T49	Spec_cue 1236 1244	sospecha
T50	LIVB 1290 1299	pacientes
#34	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Date 1343 1348	ahora
T55	GENE 852 856	BRAF
#35	AnnotatorNotes T55	C0812241; BRAF gene; Gene or Genome
T52	LIVB 438 445	Varones
#36	AnnotatorNotes T52	C0025266; Male population group; Population Group
T41	GENE 998 1002	BRAF
#37	AnnotatorNotes T41	C0812241; BRAF gene; Gene or Genome
T42	GENE 1032 1036	BRAF
#38	AnnotatorNotes T42	C0812241; BRAF gene; Gene or Genome
T43	PROC 593 616	estadificación del AJCC
#39	AnnotatorNotes T43	C1971458; American Joint Committee on Cancer (AJCC) stage documented and reviewed (ONC); Health Care Activity
T47	PROC 469 485	Estado funcional
#40	AnnotatorNotes T47	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T53	PROC 629 645	histológicamente
#41	AnnotatorNotes T53	C0344441; Histology Procedure; Laboratory Procedure
A1	Assertion T27 Negated
A2	Assertion T25 Negated
A3	Assertion T26 Negated
A4	Assertion T46 Negated
A5	Assertion T18 Speculated
A6	Status T27 History_of
A7	Status T18 History_of
#42	AnnotatorNotes T4	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#43	AnnotatorNotes T28	C0475358; Tumor tissue sample; Tissue
#44	AnnotatorNotes T14	C1879847; Biomarker Analysis; Laboratory Procedure
#45	AnnotatorNotes T10	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
#46	AnnotatorNotes T26	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
T54	Observation 1022 1064	estado de BRAF indeterminado o desconocido
A8	Assertion T54 Negated
T58	Neg_cue 1003 1005	ni
R1	Negation Arg1:T58 Arg2:T54	
R2	Negation Arg1:T45 Arg2:T26	
R3	Location_of Arg1:T55 Arg2:T10	
R4	Location_of Arg1:T41 Arg2:T26	
R5	Location_of Arg1:T42 Arg2:T26	
R6	Negation Arg1:T45 Arg2:T46	
T59	Result_or_Value 535 540	0 ó 1
T60	Observation 102 113	irresecable
#47	AnnotatorNotes T60	C4039777; Tumor surgically unresectable; Finding
R7	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T60	
R8	Before Arg1:T24 Arg2:T1	
R9	Experiences Arg1:T36 Arg2:T34	
R10	Experiences Arg1:T36 Arg2:T5	
R11	Experiences Arg1:T36 Arg2:T6	
T61	Observation 253 264	irresecable
#48	AnnotatorNotes T61	C4039777; Tumor surgically unresectable; Finding
R12	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T61	
R13	Negation Arg1:T37 Arg2:T27	
R14	Overlap Arg1:T7 Arg2:T38	
R15	Before Arg1:T6 Arg2:T3	
R16	Experiences Arg1:T36 Arg2:T3	
R17	Has_Age Arg1:T39 Arg2:T40	
R18	Has_Age Arg1:T52 Arg2:T40	
T62	CONC 490 524	Eastern Cooperative Oncology Group
#49	AnnotatorNotes T62	C1520224; ECOG performance status; Intellectual Product
T63	CONC 526 530	ECOG
#50	AnnotatorNotes T63	C1520224; ECOG performance status; Intellectual Product
R19	Has_Result_or_Value Arg1:T63 Arg2:T59	
R20	Used_for Arg1:T63 Arg2:T47	
R21	Used_for Arg1:T62 Arg2:T47	
R22	Has_Result_or_Value Arg1:T62 Arg2:T59	
T64	Observation 647 658	irresecable
#51	AnnotatorNotes T64	C4039777; Tumor surgically unresectable; Finding
T65	Quantifier_or_Qualifier 556 572	estadio III o IV
R23	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T65	
R26	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T64	
R27	Negation Arg1:T44 Arg2:T25	
T66	CONC 704 714	RECIST 1.1
#52	AnnotatorNotes T66	C1709926; Response Evaluation Criteria in Solid Tumors; Intellectual Product
T67	Observation 787 798	irresecable
#53	AnnotatorNotes T67	C4039777; Tumor surgically unresectable; Finding
R29	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T67	
R30	Before Arg1:T13 Arg2:T22	
T68	Quantifier_or_Qualifier 857 864	natural
#54	AnnotatorNotes T68	C0205296; Natural; Functional Concept
R33	Has_Quantifier_or_Qualifier Arg1:T55 Arg2:T68	
T69	CONC 961 970	inclusión
A9	Assertion T69 Negated
#55	AnnotatorNotes T69	C1512693; Inclusion; Qualitative Concept
R35	Negation Arg1:T45 Arg2:T69	
R36	Experiences Arg1:T46 Arg2:T26	
R37	Experiences Arg1:T46 Arg2:T54	
R38	Location_of Arg1:T31 Arg2:T16	
R39	Location_of Arg1:T30 Arg2:T15	
R40	Location_of Arg1:T32 Arg2:T17	
T70	Quantifier_or_Qualifier 1117 1124	activas
#56	AnnotatorNotes T70	C0679217; Active State; Idea or Concept
R41	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T70	
T71	Quantifier_or_Qualifier 1214 1220	activa
#57	AnnotatorNotes T71	C0679217; Active State; Idea or Concept
R42	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T71	
R43	Speculation Arg1:T49 Arg2:T18	
R44	Before Arg1:T19 Arg2:T20	
R45	Experiences Arg1:T50 Arg2:T20	
R46	Before Arg1:T20 Arg2:T21	
R47	Overlap Arg1:T21 Arg2:T51	
R48	Experiences Arg1:T50 Arg2:T21	
T72	CONC 1362 1387	fase de extensión abierta
R49	Overlap Arg1:T21 Arg2:T72	
R50	Experiences Arg1:T36 Arg2:T27	
R28	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T67	
R31	Before Arg1:T12 Arg2:T22	
A10	Assertion T41 Negated
R24	Negation Arg1:T45 Arg2:T41	
#58	AnnotatorNotes T51	C1948052; Now (temporal qualifier); Temporal Concept
A11	Experiencer T36 Patient
A12	Experiencer T39 Patient
A13	Experiencer T52 Patient
A14	Experiencer T46 Patient
A15	Experiencer T48 Patient
R25	Experiences Arg1:T48 Arg2:T18	
A16	Experiencer T50 Patient
